Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients

Supportive Care in Cancer

Volumn 22, Issue 6, 2014, Pages 1579-1584

  Nagashima, Makoto ^a   Ooshiro, Mitsuru ^a   Moriyama, Ayako ^a   Sugishita, Yui ^a   Kadoya, Kengo ^a   Sato, Ayami ^a   Kitahara, Tomoaki ^a   Takagi, Ryuichi ^a   Urita, Tasuku ^a   Yoshida, Yutaka ^a   Tanaka, Hiroshi ^a   Oshiro, Takashi ^a   Okazumi, Shinichi ^a   Katoh, Ryoji ^a  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

Author keywords

Chemotherapy induced peripheral neuropathy; Colorectal cancer; FOLFOX; Oxaliplatin; Oxycodone

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; OXYCODONE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; COLORECTAL CANCER; CONSTIPATION; CONTROLLED DRUG RELEASE; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HALLUCINATION; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY;

AGED; ANALGESICS, OPIOID; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DELAYED-ACTION PREPARATIONS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OXYCODONE; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES;

EID: 84902314582     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2132-4     Document Type: Article

References (36)

1. Paice JA (2010) Chronic treatment-related pain in cancer survivors. Pain 152(3 suppl):S84-S89
2. Malik B, Stillman M (2008) Chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 12:165-174
3. Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA,Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472-1478
4. McWhinney SR, Goldberg RM, McLeod HL (2009) Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8:10-16
5. Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9-17 (Pubitemid 34119018)
6. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351 (Pubitemid 38702845)
7. Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL (2011) The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 19:1769-1777
8. Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG (2011) Allopregnanolone prevents and suppresses oxaliplatin-evoked painful neuropathy: multi-parametric assessment and direct evidence. Pain 152:170-181
9. Garg MB, Ackland SP (2011) Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumor effect. Cancer Chemother Pharmacol 67:963-966
10. Wilson RH, Lehky T, Thomas RR (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767-1774 (Pubitemid 34273265)
11. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC (2011) Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One 6:e18469
12. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV, Saif MW, Reardon J (2013) Chemotherapy- induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the populationbased PROFILES registry. J Clin Oncol 31:2699-2707
13. Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013) Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer 21: 3307-3313
14. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K, Watanabe T, Hausheer FH (2012) Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC02 A randomized clinical trial. Support Care Cancer 20:3355-3364
15. Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13:1389-1391
16. Eisenberg E, McNicol ED, Carr DB (2005) Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review andmeta-analysis of randomized controlled trials. JAMA 293:3043-3052 (Pubitemid 40965075)
17. Furlan AD, Sandoval JA,Mailis-Gagnon A, Tunks E (2006) Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174:1589-1594 (Pubitemid 43829515)
18. Garassino MC, Piva S, La Verde N, Spagnoletti I, Iorno V, Carbone C, Febbraro A, BianchiA, Bramati A, Moretti A, Ganzinelli M, Marabese M, Gentili M, Torri V, Farina G (2013) Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One 8:e59981
19. U.S. Department of Health and Human Services (2009) Common terminology criteria of adverse events (CTCAE) version 3.0
20. Wen F, Zhou Y, Wang W, Hu QC, Liu YT, Zhang PF, Du ZD, Dai J, Li Q (2013) Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer : a meta-analysis. Ann Oncol 24:171-178
21. Loprinzi L, Qin R, Dakhil SR, Fehrenbacher K, Stella PJ, Atherton PJ, Seisler DK, Qamar R, Lewis GC, Grothey A (2013) Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB : an alliance for clinical trials in oncology study. J Clin Oncol 31(15 suppl):3501
22. de Afonseca SO, Cruz FM, de Iracema Gomes Cubero D, Lera AT, Schindler F, Okawara M, de Souza LF, Rogrigues NP, del Giglio A (2013) Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy : a pilot randomized clinical trial. Sao Paulo Med J 131: 35-38
23. Kautio A-L, Haanpaa M, Leminen A, Kalso E, Kautiainen H, Saarto T (2009) Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. Anticancer Res 29:2601-2606
24. Rao RD,Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nickcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY, the North Central Cancer Treatment Group (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy : A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110-2118 (Pubitemid 350036873)
25. Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, Gross HM, Nashawaty M, Loprinzi CL (2008) Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy : A phase 3 randomized, double-blind, placebocontrolled trial, N01C3. Cancer 112:2802-2808 (Pubitemid 351969227)
26. Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity : results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23:200-205
27. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED,Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359-1367
28. Urch CE, Dickenson AH (2008) Neuropathic pain in cancer. Eur J Pain 44:1091-1096 (Pubitemid 351672363)
29. Watson CPN, Babul N (1998) Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50: 1837-1841 (Pubitemid 28283261)
30. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J (2003) Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105:71-78 (Pubitemid 37162475)
31. Gimbel JS, Rochards P, Portenoy RK (2003) Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60:927-934 (Pubitemid 36348923)
32. Hanna M, O'Brien C, Wilson MC (2008) Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 12:804-813
33. Cartoni C, Brunetti GA, Federico V, Efficace F, Grammatico S, Tendas A, Scaramucci L, Cupelli L, D'Elia GM, Truini A, Niscola P, Petrucci MT (2012) Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma? Support Care Cancer 20:2621-2626
34. Narita M, Nakamura A, Ozaki M, Imai S, Miyoshi K, Suzuki M, Suzuki T (2008) Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine. Neuropsychopharmacology 33: 1097-1112 (Pubitemid 351367533)
35. Minami K, Hasegawa M, Ito H, Nakamura A, Tomii T, Matsumoto M, Orita S,Matsushima S,Miyoshi T, Masuno K, ToriiM, Koike K, Shimada S, Kanemasa T, Kihara T, Narita M, Suzuki T, Kato A (2009) Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci 111:60-72
36. Frigeni B, Piatti M, Lanzani F, Alberti P, Villa P, Zanna C, Ceracchi M, Ildebrando M, Cavaaletti G (2011) Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 16:228-236